Xenon scores up to $646m in Genentech pain deal
This article was originally published in Scrip
Executive Summary
Vancouver-based Xenon Pharmaceuticals stands to receive up to $646 million in milestones under a deal it has signed with Roche's Genentech for the discovery and development of compounds to treat pain and companion diagnostics. The deal also includes an undisclosed upfront payment and research funding, plus royalties on eventual sales.